SEP 2 2 2005

JC06 Rec'd PCT/PTO 22 SEP 2003

PCT

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Confirmation No.: Unknown

Ennio ONGINI, et al.

Group Art Unit: Unknown

Application No.: 10/537,439

Atty. Dkt. No.: 026220-00066

Filed: June 16, 2005

DRUGS FOR CHRONIC PAIN

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450


September 22, 2005

Sir:

For:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the information item(s) listed on the attached Form PTO-SB/08a and PTO-SB/08b. Unless otherwise indicated herein, one copy of each item(s) is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the item(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

XI	mailin	This Information Disclosure Statement is being filed (a) within three is of the U.S. filing date or the date of filing a CPA, OR (b) before the g date of a first Office Action on the merits in the present application, or (c) apanies a Request for Continued Examination. No certification or fee is ed.
		This Information Disclosure Statement is being filed more than three is after the U.S. filing date AND after the mailing date of the first Office on the merits, but before the mailing date of a Final Rejection or Notice of ance.
		a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
		b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).



Richard J. Berman Registration No. 39,107

Customer No. 004372 Arent Fox PLLC 1050 Connecticut Avenue, N.W., Suite 400 Washington, D.C. 20036-5339

Tel: (202) 857-6000 Fax: (202) 638-4810

RJB:cs

Enclosures: Form PTO-SB/08a; Form PTO-SB/08b; References (7)

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction

Substitute for form 1449A/PTO

1

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Form PTO/SB/08a

of

are	required to respond to a collection	on of information unless it contains a valid OMB control number.
		Complete if Known
	Application Number	10/537,439
	Filing Date	June 16, 2005
	First Named Inventor	Ennio ONGINI, et al.
	Art Unit	
	Examiner Name	
	Attorney Docket Number	026220-00066

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number	Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document	Country Code ³	Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
		95/09831	wo	A1	04-13-1995	NICOX LIMITED		
		95/30641	wo	A1	11-16-1995	NICOX LIMITED		
		00/76958	wo	A2	12-21-2000	WARNER-LAMBERT COMPANY		
		01/12584	wo	A2	02-22-2001	NICOX S.A.		
	-		_	-				
	<u> </u>							
	1							

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanesse patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

PTO/SB/08b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ns are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction

Substitute for form 1449B/PTO

Sheet

Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Form PTO/SB/08b

	Complete if Known	
Application Number	10/537,439	
Filing Date	June 16, 2005	
First Named Inventor	Ennio ONGINI, et al.	
Art Unit		
Examiner Name		
Attorney Docket Number	026220-00066	

		NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1							
		Gary J. BENNETT, et al.; A PERIPHERAL MONONEUROPATHY IN RAT THAT PRODUCES DISORDERS OF PAIN SENSATION LIKE THOSE SEEN IN MAN; Neurobiology and Anesthesiology Branch, National Institute of Dental Research, National Institutes of Health, Bethesda, MD 20892 (U.S.A), pp. 87-107	-					
		M.W. RADOMSKI, et al; THE ANTI-AGGREGATING PROPERTIES OF VASCULAR ENDOTHELIUM: INTERACTIONS BETWEEN PROSTACYCLIN AND NITRIC OXIDE, The Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS, The Macmillan Press Ltd 1987, pp. 640-646						
		James E. F. REYNOLDS, et al.; MARTINDALE THE EXTRA PHARMACOPOEIA, Thirtieth Edition, The Pharmaceutical Press, London, 1993 p. 374						
								
	ļ <u> </u>							
Examiner		Date						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *3 Enter Office that issued the document, by the two-letter code. *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

Considered